STARSurg Birmingham Journal Club Synopsis
-
Upload
starsurg -
Category
Health & Medicine
-
view
204 -
download
0
Transcript of STARSurg Birmingham Journal Club Synopsis
![Page 1: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/1.jpg)
Impact of postoperative non-steroidal anti-inflammatory drugs on adverse events after gastrointestinal surgery
Dmitri Nepogodiev
Department of Colorectal Surgery
![Page 2: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/2.jpg)
Paper
STARSurg Collaborative. Impact of postoperative non-steroidal anti-inflammatory drugs on adverse events after gastrointestinal surgery. Br J Surg. 2014 Oct;101(11):1413-23.
![Page 3: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/3.jpg)
Journal British Journal of Surgery.
Top-5 general surgery journal.
Impact factor 5.21.
![Page 4: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/4.jpg)
Authors Student Audit and Research in Surgery (STARSurg).
National, student-led research collaborative.
Founded in 2013.
Core aim: To engage medical students in high quality research, enthusing them and equipping them with the skills to become research-active consultants in the future.
![Page 5: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/5.jpg)
Steering Committee
• Chetan Khatri
• Michael Kelly
• Stephen Chapman
• James Glasbey
• Dmitri Nepogodiev
• Edward Fitzgerald
• Aneel Bhangu
![Page 6: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/6.jpg)
Primary aim To determine the safety profile of post-operative NSAIDs following gastro-intestinal resection.
![Page 7: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/7.jpg)
NSAIDs Non-steroidal anti-inflammatory drugs.
Cyclooxygenase-1 & cyclooxygenase-2 inhibitors
Inhibit prostaglandin and thromboxane synthesis.
Adverse effects include:
Gastrointestinal bleeding.
Myocardial infarction.
![Page 8: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/8.jpg)
WHO pain ladder
![Page 9: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/9.jpg)
NSAIDs and GI surgery Safety concerns – anastomotic leak.
Klein (BMJ, 2012)
Multi-centre database study.
2,766 patients.
Diclofenac and ibuprofen associated with increased risk of leak versus controls: 12.8% and 8.2% v 5.1% (P<0.001)
![Page 10: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/10.jpg)
Risk of anastomotic leak
![Page 11: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/11.jpg)
Risk of anastomotic leak
![Page 12: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/12.jpg)
Risk of anastomotic leak
![Page 13: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/13.jpg)
Risk of anastomotic leak
![Page 14: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/14.jpg)
Hypothesis The 30-day adverse event rate, following risk adjustment, should be equivalent in patients taking and not taking NSAIDs post-operatively following gastrointestinal resection.
![Page 15: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/15.jpg)
Hypothesis Population: patients undergoing bowel resection.
Intervention: post-op NSAID administration.
Control: patients not administered NSAIDs post-op.
Outcome: 30-day adverse event rate.
![Page 16: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/16.jpg)
Study design Multi-centre study.
Prospective cohort.
![Page 17: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/17.jpg)
STARSurg Network
![Page 18: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/18.jpg)
Inclusion criteria Adults.
Gastrointestinal resection. Complete transection and removal of a segment of
rectum, colon, small bowel, stomach or oesophagus.
Elective or emergency procedures.
Open or laparoscopic procedures.
![Page 19: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/19.jpg)
Primary outcome Major morbidity rate at 30-days.
Clavien-Dindo complication grades III-V.
![Page 20: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/20.jpg)
Clavien-DindoI – deviation from standard post-op course within ‘allowed therapeutic regimes’
II – complication requiring pharmacological intervention
III – complication requiring surgical, endoscopic or radiological intervention
IV – complication requiring ICU admission
V – death
Min
or
Majo
r
![Page 21: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/21.jpg)
Follow-up 30-day follow-up based on hospital records.
![Page 22: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/22.jpg)
Power calculation Detect increase in 30-day major complications from 15 to 25%.
1:2 ratio experimental to control patients.
300 patients on NSAIDs, 600 controls.
Power = 80%, alpha = 0.05.
![Page 23: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/23.jpg)
Statistics Propensity score matching.
Estimates the effect of an intervention by accounting for co-variables that predict receipt of the treatment.
Variables selected a priori:
Age, gender, ASA grade, RCRI, timing of surgery, indication, type of surgery, use of laparoscopy.
![Page 24: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/24.jpg)
Quality assurance Mandatory e-learning module.
![Page 25: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/25.jpg)
Quality assurance Compulsory to have a doctor in data collection team.
![Page 26: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/26.jpg)
Quality assurance External data validation:
5% data points validated.
>98% accuracy.
![Page 27: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/27.jpg)
Methods summary
![Page 28: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/28.jpg)
Results 1513 patients.
76% colorectal.
60% anastomosis.
109 centres.
Mean age 64.7 years
35% ASA III-V.
![Page 29: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/29.jpg)
Results: NSAID use Days 1-3 post-op, 19% of patients received NSAIDs.
Ibuprofen most commonly prescribed NSAID (70%).
![Page 30: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/30.jpg)
Results: complications Overall, 62% of patients experienced complications.
45% experienced minor (Clavien-Dindo I-II).
17% experienced major (Clavien-Dindo III-V).
Anastomotic leak rate was 4.9%.
![Page 31: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/31.jpg)
Results
![Page 32: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/32.jpg)
Results: NSAIDS Post-op NSAID administration associated with 28% reduction in overall complications.
36% reduction in patients receiving high dose NSAIDs.
Results persistent after propensity score matching.
![Page 33: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/33.jpg)
Conclusions Early NSAID associated with reduction in total complications following GI resection.
No evidence of increase in anastomotic leaks.
Underlying mechanism for reduction in complications unclear.
Reduction in opiate consumption.
Anti-inflammatory properties.
![Page 34: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/34.jpg)
Limitations Narrow data-collection window.
High level of data completeness.
Heterogenity.
Pragmatic, real-world population.
Addressed by matching.
![Page 35: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/35.jpg)
Limitations Selection bias.
Propensity score matching (RCRI, ASA).
Other analgesics used not evaluated.
Including pre-operative NSAIDs.
![Page 36: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/36.jpg)
Limitations Analysis of leak rate under-powered.
Difficult to power a 5% event rate.
Quality assurance.
Prospective, but case ascertainment unknown.
![Page 37: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/37.jpg)
Study aims:
To establish compliance with NICE guidelines requiring early identification of obese patients.
To determine the role of obesity as a risk factor for major post-operative complications in current UK and Irish practice.
![Page 38: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/38.jpg)
Inclusion criteria:
All consecutive adult patients with an overnight stay in hospital, undergoing gastrointestinal surgery or hepatobiliary surgery.
Powered to detect increase in adverse event rate in obese (BMI > 30) patients versus normal weight patients (NMI 18.5-25) from 8% to 10%.
![Page 39: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/39.jpg)
Highlights
Representation across all UK & Irish medical schools.
More detailed outcome data collection.
More thorough quality assurance.
REDCap.
£12,000 awarded by INSPIRE.
Integrated research skills course & buddy scheme.
![Page 40: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/40.jpg)
Scope for RCT? Population?
Bowel resection versus all major GI surgery
Intervention?
Pre-operative NSAID?
Peri-operative ketorolac?
Post-operative NSAID? (High dose? Early?)
![Page 41: STARSurg Birmingham Journal Club Synopsis](https://reader036.fdocuments.net/reader036/viewer/2022062405/556b13a2d8b42ae47d8b517b/html5/thumbnails/41.jpg)
Scope for RCT? Comparison
Protocolised analgesia or pragmatic?
Outcome
Morbidity?
Return to bowel function? LOS?
PROMS?